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Abstract
Disease Overview: Approximately one-fourth of primary cutaneous lymphomas are
B-cell derived and are generally classified into three distinct subgroups: primary cuta-
neous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma
(PCMZL), and primary cutaneous diffuse large B-cell lymphoma, leg type
(PCDLBCL, LT).
Diagnosis: Diagnosis and disease classification is based on histopathologic review
and immunohistochemical staining of an appropriate skin biopsy. Pathologic review
and an appropriate staging evaluation are necessary to distinguish primary cutaneous
B-cell lymphomas from systemic B-cell lymphomas with secondary skin involvement.
Risk-Stratification: Disease histopathology remains the most important prognostic
determinant in primary cutaneous B-cell lymphomas. Both PCFCL and PCMZL are
indolent lymphomas that infrequently disseminate to extracutaneous sites and are
associated with 5-year survival rates that exceed 95%. In contrast, PCDLBCL, LT is
an aggressive lymphoma with an inferior prognosis.
Risk-Adapted Therapy: Both PCFCL and PCMZL patients with solitary or relatively
few skin lesions may be effectively managed with local radiation therapy. While
single-agent rituximab may be employed for patients with more widespread skin
involvement, multi-agent chemotherapy is rarely appropriate. In contrast, manage-
ment of patients with PCDLBCL, LT is comparable to the management of patients
with systemic DLBCL.
1 | DISEASE OVERVIEW
Primary cutaneous lymphomas are a heterogeneous group of
extranodal non-Hodgkin lymphomas, approximately 25% of which are
B-cell derived and are classified into three major entities in the 2018
World Health Organization (WHO)-European Organization for
Research and Treatment of Cancer (EORTC) joint classification: pri-
mary cutaneous follicle-center lymphoma (PCFCL), primary cutaneous
diffuse large B-cell lymphoma, leg type (PCDLBCL, LT), and primary
cutaneous marginal zone lymphoma (PCMZL).1 The incidence of cuta-
neous B-cell lymphomas (CBCL) has been increasing and is currently
≈4 per million persons, based on Surveillance, Epidemiology, and End
Results (SEER) registry data, with the highest incidence rates being
reported among males, non-Hispanic whites, and adults over the age
of 50.2,3
2 | DIAGNOSIS
Diagnosis and classification of a CBCL requires an incisional, exci-
sional or 4-6 mm punch biopsy, which includes reticular dermis and
subcutaneous fat for morphologic and immunohistochemical analysis,
and an appropriate staging evaluation to exclude systemic disease.4
The use of appropriate immunohistochemical stains (eg, for CD5,
cyclin D1) may also aid in distinguishing CBCL from secondary skin
involvement by a systemic lymphoma.
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2.1 | Primary cutaneous follicle center lymphoma
PCFCL commonly present as a solitary purple to pink colored papule
(often biopsied to rule out a non-melanoma skin cancer) or as multiple
papules, plaques or tumors with a rim of peripheral erythema occur-
ring on the forehead, neck and upper back in middle-aged adults.
While grouped lesions may be observed, multifocal disease is less
common, as are less common presentations, including rhinophyma
and scarring alopecia with tumid pink plaques. Dermoscopy may help
differentiate these cutaneous lymphomas from more common non-
melanoma skin cancers.5 Histopathologically, PCFCL are characterized
by a follicular, diffuse, or mixed growth pattern comprised of large
centrocytes and variable centroblasts derived from germinal-center B
cells.6-8 In contrast to systemic follicular lymphomas, the majority of
PCFCL do not harbor the t(14;18) translocation involving the bcl-2
locus, and do not strongly express bcl-2 by immunohistochemistry,
although expression may be observed in a minority of cases.9-12
Strong expression of bcl-2 and CD10 may suggest secondary cutane-
ous involvement by follicular lymphoma. PCFCLs express bcl-6, vari-
ably express CD10, and are MUM-1/IRF-4, FOXP1 and IgM negative,
consistent with their origin from germinal-center B cells.
2.2 | Primary cutaneous diffuse large B-cell
lymphoma, leg type
PCDLBCL, leg type commonly affects elderly women and presents
with rapidly progressive red brown to blue tumors involving either
one or both lower legs.12,13 Tumors may be ulcerated, and larger
tumors may be surrounded by smaller satellite lesions. Less common
presentations include verrucous and multicolored nodules. Approxi-
mately 10%-15% of cases may involve other cutaneous sites apart
from the lower legs, and extracutaneous dissemination is common.12
These lymphomas are characterized by diffuse sheets of centroblasts
and immunoblasts that spare the epidermis, but frequently extend
deep into the dermis and subcutaneous tissue. In contrast to PCFCL,
lymphoma cells highly express bcl-2, likely due to gene amplifica-
tion,14,15 as t(14;18) is not observed in PCDLBCL, LT. Dual expression
of both bcl-2 and c-myc is common, and is associated with inferior
overall survival compared with the minority of PCDLBCL, LT that do
not express c-myc.15 Thus c-myc translocations (and “double hits”) are
rare among PCDLBCL, LT.15 Most cases are MUM-1/IRF-4, FOXP1,
IgM and bcl-6 positive, CD10 negative, and have a gene expression
profile resembling activated B cells.8 Perhaps not surprisingly, the
genetic landscape observed in PCDLBCL, LT is similar to that
observed in activated B-cell-type diffuse large B-cell lymphoma (ABC-
DLBCL), with NF-κB-activating mutations being observed in CD79B,
CARD11, and MYD88.16-19 Of these, somatic MYD88L265P mutations
appear most common with a prevalence of ≈75%.15,17-19 Loss of
CDKN2A has also been identified in a large number of DLBCL-LT
patients.20 Despite the use of somatically hypermutated immunoglob-
ulin heavy-chain variable (IGHV) regions, Staphylococcal superantigen
binding sites within the IGHV are preserved, thus implicating
superantigen-dependent B-cell receptor signaling in disease
pathogenesis.21
2.3 | Primary cutaneous marginal zone lymphoma
Patients with PCMZL frequently present with solitary asymptomatic
pink papule on the trunk, arm and head and neck area, or as red
brown multifocal papules, plaques or nodules involving the trunk and
arms. While an association with Borrelia burgdorferi has been observed
in Europe, a similar association has not been observed in cases from
the United States.22-25 Primary cutaneous marginal zone lymphoma
are composed of a variably mixed infiltrate of small, “centrocyte-like”
marginal zone B cells, monocytoid B cells, lymphoplasmacytic cells,
plasma cells, cells resembling centroblasts and immunoblasts, and
reactive T cells. Marginal zone B cells characteristically express bcl-2
and may express CD43, but lack bcl-6, CD10, CD5 and CD23 expres-
sion. Recently, two groups of PCMZL have been identified.1,26-28 The
majority of PCMZL express class-switched immunoglobulin and show
an indolent course; some have recommended that this type of PCMZL
should be considered a lymphoproliferative disorder to reflect its clini-
cal and histopathologic overlap with atypical reactive B-cell infiltrates
(pseudo B-cell lymphomas). A second group expresses IgM and shows
a behavior similar to extracutaneous extranodal marginal zone lym-
phomas, with frequent recurrences and extracutaneous spread.
3 | RISK STRATIFICATION
The International Society for Cutaneous Lymphomas (ISCL) and
EORTC recently proposed staging recommendations for cutaneous
lymphomas other than mycosis fungoides and Sézary syndrome.4
Staging should include a history, physical examination, and imaging
(either CT, PET, or increasingly PET/CT) of the chest, abdomen, pelvis,
and neck (in cases with involvement of the head or neck). A bone mar-
row biopsy and aspirate should be performed in cases of PCDLBCL,
LT. The joint ISCL/EORTC does not endorse routine bone marrow
examination in cases of PCFCL or PCMZL, although approximately
10% of patients with follicle center lymphomas have bone marrow
involvement and in most of these patients, the bone marrow is the
only site of extracutaneous disease.29 Bone marrow involvement was
associated with significantly inferior disease-specific survival. While
the TNM staging classification describes the extent of disease, staging
in CBCL is of limited prognostic value, as the disease histopathology is
the major determinant in risk-stratification. This is highlighted by a
population-based study which identified histopathology and the site
of skin involvement as important prognostic factors.30 In contrast, the
International Extranodal Lymphoma Study Group identified three
independent prognostic factors (ie, elevated LDH, >2 skin lesions, and
nodular lesions) among patients with PCFCL and PCMZL. These fac-
tors were combined to form the cutaneous lymphoma international
prognostic index (CLIPI). The absence of any adverse prognostic factor
was associated with a 5-year progression-free survival of 91%. In
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contrast, the presence of two or three adverse prognostic factors was
associated with a 5-year progression-free survival of 48%. As the vast
majority of relapses were confined to the skin, the CLIPI was unable
to risk-stratify patients by overall survival. The presence of multiple
skin lesions was associated with inferior disease-free survival in a
European series,31 but was not associated with disease-free survival
in a large North American series.32 The most important factor for risk-
stratification among the cutaneous B-cell lymphomas remains the his-
topathologic classification. Indolent CBCL (PCFCL and PCMZL) are
associated with 5-year disease-specific survival ≥95%,6,32 though
PCMZL with IgM expression have been associated with a more
aggressive course. Differences in growth pattern, the density of
centroblasts, and cytogenetic findings do not appear to provide mean-
ingful prognostic information in PCFCL. Although numbers are limited,
some authors have found that PCFCL occurring on the leg have a
worse prognosis and are more likely to have an immunophenotype
that overlaps with DLBCL-LT12,33 These authors suggest that consid-
eration should be given to systemic chemotherapy in such patients. In
contrast, PCDLBCL, LT is associated with a 5-year disease-specific
survival of approximately 50%, and dual bcl-2 and c-myc expres-
sion6,15,17,34 and loss of CDKN2A are associated with inferior sur-
vival.20 The presence of a somatic MYD88L265P mutation is also
associated with inferior disease-specific and overall survival.17 In con-
trast to patients presenting with only a single tumor, involvement of
multiple sites, on one or both legs, is associated with a significantly
inferior disease-specific survival.35
4 | TREATMENT
As no randomized controlled trials are available, treatment recommen-
dations for CBCL are largely based on small retrospective studies and
institutional experience. The EORTC and ISCL have published consen-
sus treatment recommendations that are consistent with NCCN
guidelines.36 In most cases, optimal patient management requires a
multidisciplinary approach, including dermatology, medical oncology
and radiation oncology.
4.1 | Primary cutaneous follicle center lymphoma
For patients with solitary lesions, low-dose radiation therapy is safe and
highly affective, with a complete remission rate approaching 100%.
Radiation does not appear inferior to multi-agent chemotherapy among
patients with multiple lesions that can be included in multiple radiation
fields.37 In a large North American series, the rate of local control for
indolent CBCL with radiation alone was 98%.32 In the same series, a
local recurrence requiring radiation therapy was observed in 25% of
patients who had undergone surgical excision alone. Reserving radiation
until disease recurrence did not appear to compromise disease-specific
or overall survival.32 Therefore, complete excision alone, deferring radia-
tion until disease recurrence, is also reasonable. Intralesional [eg, cortico-
steroids or rituximab38] or topical therapies including corticosteroids,
nitrogen mustard and bexarotene may also be considered.39,40 While
radiation therapy is generally recommended for patients with a solitary
lesion, radiation therapy or observation (ie, “watch and wait”) are rea-
sonable options for those patients with multiple lesions. Rarely, patients
with PCFCL may show a locally aggressive course41,42 and some have
suggested the possibility of transformation to DLBCL,43,44 suggesting
that “watch and wait” patients require close clinical follow-up. Patients
with more extensive skin involvement are effectively managed with
single-agent rituximab.36 Approximately one-third of patients may
relapse following either radiation or single-agent rituximab, but relapses
are usually confined to the skin and are approached in a manner similar
to that described for the initial management of PCFCL.
4.2 | Primary cutaneous marginal zone lymphoma
Patients with PCMZL are approached in a manner analogous to that
described in the initial management of PCFCL. Radiation therapy or
surgical excision are associated with high response rates for patients
with a single or few lesions.36 Those with more widespread skin
involvement may be observed. Once symptomatic, culprit lesions may
be irradiated or surgically excised.45 As for PCFCL, single-agent
rituximab may be utilized in patients with symptomatic, widespread
skin lesions. An initial trial of antibiotics for those with B. burgdorferi-
associated PCMZL has been recommended,46 but is less relevant for
North American patients.
4.3 | Primary cutaneous diffuse large B-cell
lymphoma, leg type
As previously noted, the natural history of PCDLBCL, LT more closely
resembles that of systemic DLBCL. Therefore, R-CHOP (with or with-
out radiation therapy) is utilized in these patients. While few reports
are available in the literature, the use of R-CHOP in these patients is
associated with disease-free survival rates rivaling those reported for
patients with high-risk systemic DLBCL.12,13,32,36 Most patients pre-
sent with disease confined to the leg(s) and are managed like patients
with limited stage systemic DLBCL with R-CHOP and involved field
radiation therapy. The management of relapsed disease is comparable
to that for relapsed systemic ABC-DLBCL (eg, lenalidomide,47
ibrutinib48). In a small phase II study (n = 19), the 6-month overall
response rate with single-agent lenalidomide in relapsed/refractory
PCDLBCL, LT was 26%, but was significantly higher in patients with-
out the MYD88L265P mutation.49
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